{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:49:22Z","timestamp":1791362962903,"version":"4.3.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T00:00:00Z","timestamp":1327536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Conflicting results have been reported regarding the ability of valproic acid (<jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content>) to reduce the size of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> reservoirs in patients receiving suppressive highly active antiretroviral therapy (<jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content>). In a randomized multicentre, cross\u2010over study, we assessed whether adding <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> to stable <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> could potentially reduce the size of the latent viral reservoir in <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 T cells of chronically infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 56 virologically suppressed patients were randomly assigned either to receive <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> for 16 weeks followed by <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> alone for 32 weeks (arm 1; <jats:italic>n<\/jats:italic>\u2009=\u200927) or to receive <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> alone for 16 weeks and then <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> plus <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> for 32 weeks (arm 2; <jats:italic>n<\/jats:italic>\u2009=\u200929). <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> was administered at a dose of 500\u2009mg twice a day (bid) and was adjusted to the therapeutic range. A quantitative culture assay was used to assess <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> reservoirs in <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 T cells at baseline and at weeks 16 and 48.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant reductions in the frequency of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4 <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content> cells harbouring replication\u2010competent <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> after 16 and 32 weeks of <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> therapy were observed. In arm 1, median (range) values of <jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content> per log<jats:sub>10<\/jats:sub> billion (<jats:styled-content style=\"fixed-case\">IUPB<\/jats:styled-content>) cells were 2.55 (range 1.20\u20134.20), 1.80 (range 1.0\u20134.70) and 2.70 (range 1.0\u20133.90; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.87) for baseline, week 16 and week 48, respectively. In arm 2, median values of <jats:styled-content style=\"fixed-case\">IUPB<\/jats:styled-content> were 2.55 (range 1.20\u20134.65), 1.64 (range 1.0\u20133.94) and 2.51 (range 1.0\u20134.48; <jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009=\u20090.50) for baseline, week 16 and week 48, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study demonstrates that adding <jats:styled-content style=\"fixed-case\">VPA<\/jats:styled-content> to stable <jats:styled-content style=\"fixed-case\">HAART<\/jats:styled-content> does not reduce the latent <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> reservoir in virally suppressed patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2011.00975.x","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T11:05:19Z","timestamp":1327575919000},"page":"291-296","source":"Crossref","is-referenced-by-count":104,"title":["Valproic acid in association with highly active antiretroviral therapy for reducing systemic <scp>HIV<\/scp>\u20101 reservoirs: results from a multicentre randomized clinical study"],"prefix":"10.1111","volume":"13","author":[{"given":"JP","family":"Routy","sequence":"first","affiliation":[{"name":"Division of Hematology Royal Victoria Hospital, McGill University Health Centre  Montreal QC Canada"},{"name":"Immunodeficiency Service, Montreal Chest Institute McGill University Health Centre  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CL","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l\u2032Universit\u00e9 de Montr\u00e9al  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JB","family":"Angel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Department of Medicine Ottawa Hospital, University of Ottawa  Ottawa ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Trottier","sequence":"additional","affiliation":[{"name":"Clinique M\u00e9dicale l'Actuel  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l\u2032Universit\u00e9 de Montr\u00e9al  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JG","family":"Baril","sequence":"additional","affiliation":[{"name":"Clinique M\u00e9dicale du Quartier Latin Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, Universit\u00e9 de Montr\u00e9al  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Harris","sequence":"additional","affiliation":[{"name":"Canadian HIV Trial Network\/Canadian Institutes of Health Research University of British Columbia  Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Trottier","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec  Sainte\u2010Foy QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Singer","sequence":"additional","affiliation":[{"name":"AIDS Research Program St Paul's Hospital  Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Chomont","sequence":"additional","affiliation":[{"name":"VGTI Florida  Port St Lucie FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RP","family":"S\u00e9kaly","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l\u2032Universit\u00e9 de Montr\u00e9al  Montreal QC Canada"},{"name":"VGTI Florida  Port St Lucie FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MR","family":"Boulassel","sequence":"additional","affiliation":[{"name":"Division of Hematology Royal Victoria Hospital, McGill University Health Centre  Montreal QC Canada"},{"name":"Immunodeficiency Service, Montreal Chest Institute McGill University Health Centre  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328340a239"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm880"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600900"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-009-0033-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01208-07"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.05.040"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200405210-00003"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67098-5"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67074-2"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000238421.36313.fa"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/511823"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fd6ddc"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fd6df4"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009390"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.05.005"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1128\/JCM.38.11.4246-4248.2000","article-title":"Marked differences in quantity of infectious human immunodeficiency virus type 1 detected in persons with controlled plasma viremia by a simple enhanced culture method","volume":"38","author":"Tremblay CL","year":"2000","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2223"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/649569"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000321"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1972"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2011.00975.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2011.00975.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:46:06Z","timestamp":1700585166000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2011.00975.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1468-1293.2011.00975.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2011.00975.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,26]]}}}